Clinical trials: Dyspnoea
Chronic Obstructive Pulmonary Disease
Ryme Medical TLD Pilot Study
Targeted lung denervation (TLD) with the Ryme Medical Lung Denervation System in patients with chronic obstructive pulmonary disease (COPD) - Ryme Medical TLD Pilot Study
- Trial name
- NCT05967091
- Testing
- Targeted Lung Denervation
- Where
- 7 sites in Australia, Austria and 4 more
- Volunteers
- 60 people
- Sponsor
- Ryme Medical, Inc.
Heart Failure, Congestive, Dyspnea
The DIAMOND Study: Distensibility Improvement And Remodeling in Diastolic Heart Failure
The purpose of this study is to test the hypothesis that treatment with oral ALT-711 twice daily for 16 weeks will improve aortic distensibility, exercise tolerance, and quality of life in elderly patients with isolated diastolic…
- Conditions
- Heart Failure, Congestive, Dyspnea, Pulmonary Edema
- Trial name
- NCT00043836
- Testing
- ALT-711
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Synvista Therapeutics, Inc
Asthma
Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma
This was a randomized, placebo-controlled, double-blind, six-sequence, three-period cross-over study in asthma patients. The study consisted of a 14-day screening period, followed by a 14-day run-in period, and a treatment epoch…
- Trial name
- QVM149 (NCT03108027)
- Where
- 7 sites in Germany, Netherlands and 1 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)
This study evaluated the effect of QAB149 on dynamic and static hyperinflation, breathlessness, and health status in COPD patients
- Trial name
- NCT00636961
- Testing
- Indacaterol 300μg
- Where
- 3 sites in Germany
- Volunteers
- 27 people
- Sponsor
- Novartis
Dyspnea, Hypercapnia
Clinical Efficacy in Relief of Dyspnea by HVNI: Evaluation of New Cannulae Designs
This study will evaluate the ability of High Velocity Nasal Insufflation [HVNI] next generation nasal cannula designs to effect ventilation and related physiological responses relative to the conventional legacy cannula design.
- Conditions
- Dyspnea, Hypercapnia, Respiratory Insufficiency
- Trial name
- NCT04512781
- Testing
- Control Cannula - Prosoft Cannula - Unicorn Cannula, Control Cannula - Unicorn Cannula - Prosoft Cannula
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Vapotherm, Inc.
COPD, ILD
Individualized Plan for Improving Adherence to Portable Oxygen Therapy in Patients With Respiratory Pathology
Pilot study with patients with prescription of portable oxygen therapy, to test the impact on adherence of a patient-centered empowerment program, with contents on the nature of the respiratory pathology, the symptom of dyspnea…
- Conditions
- COPD, ILD, Dyspnea
- Trial name
- PIMAOX (NCT04691336)
- Testing
- Educational and Training with counselling
- Where
- Spain
- Volunteers
- 22 people
- Sponsor
- Air Liquide Healthcare Spain
Pulmonary Disease, Chronic Obstructive
SERETIDE Plus Tiotropium Versus Individual Components
This study was designed to evaluate the effects on lung function of a combination of SERETIDE 50/500mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual treatments (tiotropium bromide 18mcg once…
- Trial name
- NCT00325169
- Testing
- Tiotropium + SERETIDE 50/500
- Where
- 5 sites in Belgium, United Kingdom
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)
This study compared the safety and efficacy of indacaterol 150 µg taken once daily (o.d.) versus salmeterol 50 µg taken twice daily (b.i.d) in patients 40 years old or older with chronic obstructive pulmonary disease.
- Trial name
- INSIST (NCT00821093)
- Testing
- Indacaterol 150 µg, Salmeterol 50 µg
- Where
- 144 sites in United States, Czechia and 6 more
- Volunteers
- 1,123 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
This study is a randomized, double-blind, placebo-controlled, three-period cross-over study in approximately 54 subjects with asthma.
- Trial name
- NCT03257995
- Testing
- Indacaterol maleate, Indacaterol acetate
- Where
- 6 sites in United States
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Congestive, Heart Decompensation
A Study to Develop Additional Safety and Clinical Experience With NATRECOR hBNP (Nesiritide) in the Treatment of Patients With Worsening Congestive Heart Failure Who Require Inpatient Intravenous Therapy With Medications That Influence the Tone and Caliber of Blood Vessels
The purpose of this safety study is to evaluate NATRECOR® hBNP (a recombinant form of the natural human peptide normally secreted by the heart in response to heart failure), in subjects with worsening congestive heart failure…
- Trial name
- NCT00271557
- Testing
- nesiritide
- Volunteers
- 305 people
- Sponsor
- Scios, Inc.
Heart Failure, Congestive
FUSION I Assesses Safety and Tolerability of Two Doses of NATRECOR (Nesiritide) Administered to Patients With Worsening Congestive (Decompensated) Heart Failure Who Are Concurrently Receiving Their Usual Cardiac Medications and Are at High Risk for Hospitalization.
The purpose of this study is to assess the safety and tolerability of two doses of nesiritide (a recombinant form of the natural human peptide normally secreted by the heart in response to heart failure) when administered…
- Trial name
- NCT00270361
- Testing
- nesiritide, usual long term cardiac medications
- Volunteers
- 214 people
- Sponsor
- Scios, Inc.
Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout
Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel
The purpose of the study is to describe patient characteristics and drug usage among patients that are prescribed ticagrelor for the first time and to compare them with patients who are prescribed clopidogrel and prasugrel for…
- Trial name
- NCT01276275
- Testing
- Risk of selected safety events
- Where
- Sweden
- Volunteers
- 7,200 people
- Sponsor
- AstraZeneca
Bronchitis, Cough
Treatment of Respiratory Tract Infection and/or Acute Bronchitis With Ectoin Inhalation Solution
This observational, non-interventional multicentric study compares the inhalation therapy on patients suffering on respiratory tract infections and/or acute bronchitis between Ectoin inhalation solution and Pari NaCl (0.9%)…
- Conditions
- Bronchitis, Cough, Sputum, Cellular Atypia, Dyspnoea
- Trial name
- NCT02632851
- Where
- Germany
- Volunteers
- 135 people
- Sponsor
- Bitop AG
Chronic Obstructive Pulmonary Disease
The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This study assessed the effect of QVA149 on patient-reported dyspnea in moderate to severe Chronic Obstructive Pulmonary Disease (COPD) patients.
- Trial name
- BLAZE (NCT01490125)
- Testing
- QVA149, Tiotropium, Salbutamol/albuterol
- Where
- 43 sites in Belgium, Canada and 3 more
- Volunteers
- 247 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Safety Study in Adolescent and Adult Patients With Asthma
E004-C2 is a continuation of E004-C for safety evaluations with additional 3 months to be able to assess the 6-month safety profile for E004 (epinephrine inhalation) versus placebo in a double-blinded manner.
- Trial name
- NCT01476904
- Testing
- Primatene Mist, Epinephrine inhalation
- Where
- 27 sites in United States
- Volunteers
- 208 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
COPD, Dyspnea
Vitabreath Pilot in Chronic Obstructive Pulmonary Disease (COPD) Patients
Dyspnea is the most common symptom limiting the ability of COPD patients to perform activities of daily living. Although there has been research involving the benefit of providing Non Invasive Ventilation (NIV) during exercise to…
- Trial name
- NCT03349437
- Testing
- Vitabreath Device, Pursed Lip Breathing
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Philips Respironics
Mucus Clearance, Respiratory Symptoms
A Study to Evaluate the Effects of a Supplement on Mucus Clearance and Respiratory Symptoms
This is a randomized, triple-blind, placebo-controlled clinical trial evaluating the effects of the BetterLungs Mullein + Chlorophyll supplement on mucus clearance and respiratory symptoms over 60 days.
- Conditions
- Mucus Clearance, Respiratory Symptoms, Breathlessness, Chest Mucus Accumulation
- Trial name
- NCT07740746
- Testing
- BetterLungs
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The Better Brand Inc.
Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic
A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD
To determine if ABX-IL8 will improve shortness of breath.
- Trial name
- NCT00035828
- Testing
- ABX-IL8
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Abgenix
Asthma
Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma
An unmet medical need exists for patients with moderate and severe asthma who continue to demonstrate symptoms despite being on standard of care medications, and are not eligible for other biologic therapies developed or in…
- Trial name
- NCT03299686
- Testing
- CJM112
- Where
- 29 sites in United States, Argentina and 6 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Covid19, Postviral Syndrome
ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome
This is a Phase I/II trial to evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EV), ExoFlo, as treatment for Post-Acute COVID-19 and Chronic…
- Conditions
- Covid19, Postviral Syndrome, Dyspnea
- Trial name
- NCT05116761
- Testing
- Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles, Saline
- Sponsor
- Direct Biologics, LLC